STOCK TITAN

[Form 4] METLIFE INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

MetLife, Inc. director Diana McKenzie acquired 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share under the company’s non‑management director compensation program. The filing states that a portion of non‑management director retainer fees are paid in common stock and that Ms. McKenzie elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non‑Management Directors. After this transaction she beneficially owns 22,757 shares, reported as direct ownership. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025. The disclosure is limited to the director grant and deferral; no additional financial results, guidance, or other transactions are included in this filing.

MetLife, Inc. direttore Diana McKenzie ha acquisito 534 azioni comuni MetLife in data 10/01/2025 al prezzo riportato di $81.93 per azione, ai sensi del programma di compenso per i direttori non esecutivi dell’azienda. Il deposito indica che una parte dei compensi di trattenuta per direttori non esecutivi è pagata in azioni comuni e che la signora McKenzie ha scelto di differire la ricezione di tali azioni ai sensi del MetLife Deferred Compensation Plan for Non‑Management Directors. Dopo questa transazione detiene, beneficialmente, 22,757 azioni, riportate come proprietà diretta. Il Form 4 è stato firmato da un procuratore in data 10/03/2025. La disclosure è limitata all’assegnazione del direttore e al differimento; non sono inclusi ulteriori risultati finanziari, guidance o altre transazioni in questo filing.

MetLife, Inc. directivo Diana McKenzie adquirió 534 acciones comunes de MetLife en la fecha 10/01/2025 a un precio informado de $81.93 por acción, en el marco del programa de compensación para directores no ejecutivos de la empresa. La presentación indica que una parte de las tarifas de honorarios de los directores no ejecutivos se paga en acciones comunes y que la Sra. McKenzie optó por diferir la recepción de estas acciones bajo el MetLife Deferred Compensation Plan for Non‑Management Directors. Después de esta operación posee beneficiosamente 22,757 acciones, reportadas como propiedad directa. El Formulario 4 fue firmado por un apoderado el 10/03/2025. La divulgación se limita a la adjudicación y al diferimiento del director; no se incluyen resultados financieros adicionales, orientación u otras transacciones en este archivo.

MetLife, Inc. 이사 Diana McKenzie534주 MetLife 보통주를 2025-10-01에 취득했고 주당 보고 가격은 $81.93로 회사의 비경영진 이사 보수 프로그램에 따라 이루어졌습니다. 제출서에 따르면 비경영진 이사 보수의 일부가 보통주로 지급되며, 맥켄지 여사는 이 주식의 수령을 MetLife Deferred Compensation Plan for Non‑Management Directors에 따라 이연하기로 선택했다고 명시되어 있습니다. 이 거래 후 그녀는 유익하게 22,757주를 보유하며 직접 소유로 보고됩니다. Form 4는 2025-10-03에 대리인에 의해 서명되었습니다. 공시는 이 이사 보상 및 이연에 국한되며, 이 제출물에는 추가 재무 결과, 안내 또는 기타 거래가 포함되어 있지 않습니다.

MetLife, Inc. administratrice Diana McKenzie a acquis 534 actions ordinaires MetLife le 01/10/2025 au prix déclaré de $81.93 par action dans le cadre du programme de rémunération des administrateurs non dirigeants de l’entreprise. Le dépôt indique qu’une partie des frais de rétention des administrateurs non dirigeants est payée en actions ordinaires et que Mme McKenzie a choisi de différer la réception de ces actions en vertu du MetLife Deferred Compensation Plan for Non‑Management Directors. Après cette opération, elle détient bénéficiairement 22,757 actions, déclarées comme propriété directe. Le Formulaire 4 a été signé par un procureur en date du 10/03/2025. La divulgation est limitée à l’attribution de l’administrateur et au report; aucune autre résultat financier, orientation ou transaction n’est inclus dans ce dépôt.

MetLife, Inc. Direktorin Diana McKenzie erwarb 534 MetLife Stammaktien am 01.10.2025 zu einem gemeldeten Preis von $81.93 pro Aktie im Rahmen des Vergütungsprogramms für nicht-führende Direktoren des Unternehmens. Die Einreichung stellt fest, dass ein Teil der Retainer-Gebühren für nicht-führende Direktoren in Stammaktien gezahlt wird und dass Frau McKenzie die Empfangsform dieser Aktien gemäß dem MetLife Deferred Compensation Plan for Non‑Management Directors hinauszögern wollte. Nach dieser Transaktion besitzt sie begünstigt 22,757 Aktien, die als unmittelbares Eigentum gemeldet werden. Das Form 4 wurde von einem Vollmachtsträger am 10/03/2025 unterzeichnet. Die Offenlegung beschränkt sich auf die Zuweisung des Direktors und die Aufschiebung; es enthält keine weiteren finanziellen Ergebnisse, Richtlinien oder anderen Transaktionen in dieser Einreichung.

MetLife, Inc. مديرة Diana McKenzie اشترت 534 سهماً من أسهم MetLife العادية في تاريخ 10/01/2025 بسعر مبلّغ عنه قدره $81.93 للسهم بموجب برنامج تعويضات مديري الشركة غير التنفيذيين. تنص الأوراق على أن جزءاً من رسوم الاحتفاظ لمديري غير التنفيذيين يُدفع بالأسهم العادية وأن السيدة ماكنزي اختارت تأجيل استلام هذه الأسهم بموجب MetLife Deferred Compensation Plan for Non‑Management Directors. بعد هذه المعاملة تمتلك بشكل مستفيد 22,757 سهماً، مبلَّغ عنها كملكية مباشرة. تم توقيع النموذج Form 4 من قبل وكيل قانوني في 10/03/2025. disclosures محدودة بالتعيين والتأجيل؛ لا تتضمن هذه الإيداع أية نتائج مالية إضافية أو توجيهات أو معاملات أخرى.

MetLife, Inc. 董事 Diana McKenzie2025-10-01 以每股 $81.93 的披露价格购买了 534 股 MetLife 普通股,符合公司非管理层董事薪酬计划。备案文件称,部分非管理层董事的订金费用以普通股支付,McKenzie 女士选择按照 MetLife Deferred Compensation Plan for Non‑Management Directors 将收取的这些股票的发放递延。交易完成后,她以直接所有权报告持有 22,757 股股票。Form 4 由代理人于 2025-10-03 签署。披露仅限于董事的授予和递延;此 filings 未包含其他财务业绩、指引或其他交易。

Positive
  • None.
Negative
  • None.

MetLife, Inc. direttore Diana McKenzie ha acquisito 534 azioni comuni MetLife in data 10/01/2025 al prezzo riportato di $81.93 per azione, ai sensi del programma di compenso per i direttori non esecutivi dell’azienda. Il deposito indica che una parte dei compensi di trattenuta per direttori non esecutivi è pagata in azioni comuni e che la signora McKenzie ha scelto di differire la ricezione di tali azioni ai sensi del MetLife Deferred Compensation Plan for Non‑Management Directors. Dopo questa transazione detiene, beneficialmente, 22,757 azioni, riportate come proprietà diretta. Il Form 4 è stato firmato da un procuratore in data 10/03/2025. La disclosure è limitata all’assegnazione del direttore e al differimento; non sono inclusi ulteriori risultati finanziari, guidance o altre transazioni in questo filing.

MetLife, Inc. directivo Diana McKenzie adquirió 534 acciones comunes de MetLife en la fecha 10/01/2025 a un precio informado de $81.93 por acción, en el marco del programa de compensación para directores no ejecutivos de la empresa. La presentación indica que una parte de las tarifas de honorarios de los directores no ejecutivos se paga en acciones comunes y que la Sra. McKenzie optó por diferir la recepción de estas acciones bajo el MetLife Deferred Compensation Plan for Non‑Management Directors. Después de esta operación posee beneficiosamente 22,757 acciones, reportadas como propiedad directa. El Formulario 4 fue firmado por un apoderado el 10/03/2025. La divulgación se limita a la adjudicación y al diferimiento del director; no se incluyen resultados financieros adicionales, orientación u otras transacciones en este archivo.

MetLife, Inc. 이사 Diana McKenzie534주 MetLife 보통주를 2025-10-01에 취득했고 주당 보고 가격은 $81.93로 회사의 비경영진 이사 보수 프로그램에 따라 이루어졌습니다. 제출서에 따르면 비경영진 이사 보수의 일부가 보통주로 지급되며, 맥켄지 여사는 이 주식의 수령을 MetLife Deferred Compensation Plan for Non‑Management Directors에 따라 이연하기로 선택했다고 명시되어 있습니다. 이 거래 후 그녀는 유익하게 22,757주를 보유하며 직접 소유로 보고됩니다. Form 4는 2025-10-03에 대리인에 의해 서명되었습니다. 공시는 이 이사 보상 및 이연에 국한되며, 이 제출물에는 추가 재무 결과, 안내 또는 기타 거래가 포함되어 있지 않습니다.

MetLife, Inc. administratrice Diana McKenzie a acquis 534 actions ordinaires MetLife le 01/10/2025 au prix déclaré de $81.93 par action dans le cadre du programme de rémunération des administrateurs non dirigeants de l’entreprise. Le dépôt indique qu’une partie des frais de rétention des administrateurs non dirigeants est payée en actions ordinaires et que Mme McKenzie a choisi de différer la réception de ces actions en vertu du MetLife Deferred Compensation Plan for Non‑Management Directors. Après cette opération, elle détient bénéficiairement 22,757 actions, déclarées comme propriété directe. Le Formulaire 4 a été signé par un procureur en date du 10/03/2025. La divulgation est limitée à l’attribution de l’administrateur et au report; aucune autre résultat financier, orientation ou transaction n’est inclus dans ce dépôt.

MetLife, Inc. Direktorin Diana McKenzie erwarb 534 MetLife Stammaktien am 01.10.2025 zu einem gemeldeten Preis von $81.93 pro Aktie im Rahmen des Vergütungsprogramms für nicht-führende Direktoren des Unternehmens. Die Einreichung stellt fest, dass ein Teil der Retainer-Gebühren für nicht-führende Direktoren in Stammaktien gezahlt wird und dass Frau McKenzie die Empfangsform dieser Aktien gemäß dem MetLife Deferred Compensation Plan for Non‑Management Directors hinauszögern wollte. Nach dieser Transaktion besitzt sie begünstigt 22,757 Aktien, die als unmittelbares Eigentum gemeldet werden. Das Form 4 wurde von einem Vollmachtsträger am 10/03/2025 unterzeichnet. Die Offenlegung beschränkt sich auf die Zuweisung des Direktors und die Aufschiebung; es enthält keine weiteren finanziellen Ergebnisse, Richtlinien oder anderen Transaktionen in dieser Einreichung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
MCKENZIE DIANA

(Last) (First) (Middle)
METLIFE, INC.
200 PARK AVENUE

(Street)
NEW YORK NY 10166

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 A(1) 534 A $81.93 22,757 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
Remarks:
/s/ Taylor McInerney Jansen, Attorney-in-fact 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did MetLife director Diana McKenzie report on Form 4 (MET)?

The Form 4 reports that 534 shares were acquired on 10/01/2025 at a price of $81.93 per share.

How many MetLife (MET) shares does Diana McKenzie beneficially own after the reported transaction?

Following the reported acquisition, she beneficially owns 22,757 shares, reported as direct ownership.

Why were the shares issued to the MetLife director?

The shares were issued as part of non‑management director retainer fees and were deferred under the MetLife Deferred Compensation Plan for Non‑Management Directors.

When was the Form 4 for the MetLife transaction executed?

The filing shows the transaction date as 10/01/2025 and the Form 4 was signed by an attorney‑in‑fact on 10/03/2025.

Was this Form 4 filed by one reporting person or jointly?

The Form indicates it was filed by one reporting person.
MetLife

NYSE:MET

MET Rankings

MET Latest News

MET Latest SEC Filings

MET Stock Data

54.09B
663.27M
0.25%
91.63%
1.37%
Insurance - Life
Life Insurance
Link
United States
NEW YORK